今日要闻！邯郸购房新政出台：多孩家庭获购房补贴和公积金贷款额度提升

邯郸购房新政出台：多孩家庭获购房补贴和公积金贷款额度提升

为贯彻落实国家关于房地产市场平稳健康发展的要求，进一步支持刚性和改善性住房需求，河北邯郸市出台了一系列优化房地产政策的措施，其中包括对购房给予1%购房补贴和提高多孩家庭公积金贷款额度等内容。

购房补贴政策

根据新政，对在邯郸市行政区域内购买新建商品住房的购房人，按照成交价的1%给予购房补贴。对到企业入职的高校毕业生、生育二胎及以上家庭、60岁及以上老人购买新建商品住房的，购房补贴额再上调0.5%。

公积金贷款额度提升

为更好地支持多孩家庭购房需求，邯郸市提高了多孩家庭公积金贷款额度。“二孩”家庭公积金最高贷款额由原来的60万元提高至80万元，“三孩”家庭公积金最高贷款额由原来的80万元提高至100万元。

其他政策

此外，新政还包括以下内容：

• 调整首套住房商业性个人住房贷款最低首付款比例至15%；
• 调整二套住房商业性个人住房贷款最低首付款比例至25%。

政策解读

邯郸市此次出台的优化房地产政策措施，体现了对刚性和改善性住房需求的支持力度，有利于促进房地产市场平稳健康发展。其中，购房补贴政策的实施，将有效减轻购房者的负担，提高购房积极性；公积金贷款额度提升，将更好地满足多孩家庭的住房需求。

下一步，邯郸市将继续加大房地产市场监管力度，严厉打击违规行为，确保房地产市场平稳健康发展。

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.